Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Certara Inc (CERT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Certara's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
17.64 +0.04    +0.23%
16:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
17.64
0.00
0.00%
17:00:24 - Real-time Data
  • Volume: 556,570
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 17.24 - 17.71
Type:  Equity
Market:  United States
Certara 17.64 +0.04 +0.23%

Certara Inc Company Profile

 
Get an in-depth profile of Certara Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustrySoftware & IT Services
SectorTechnology
Employees

1365

Equity Type

ORD

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Contact Information

Address 100 Overlook Center Suite 101
Princeton, 08540
United States
Phone 609 716 7900
Fax -

Top Executives

Name Age Since Title
Malcolm Rowland - - Chair of Simcyp Scientific Advisory Board
William F. Feehery 51 2019 CEO & Director
James E. Cashman 68 2018 Independent Chairman of the Board
Matthew M. Walsh 55 2017 Independent Director
Nancy Killefer 69 2021 Independent Director
Rosemary A. Crane 62 2022 Independent Director
Donald E. Mager - - Member of Simcyp Scientific Advisory Board
Jennifer B. Dressman - 2017 Member of Simcyp Scientific Advisory Board
Stephen M. McLean - 2013 Independent Director
David Spaight - 2022 Independent Director
Yuichi Sugiyama - - Member of Simcyp Scientific Advisory Board
Noriko Okudaira - 2019 Senior Consultant & Member of Simcyp Scientific Advisor Board
J Brian Houston - - Member of Simcyp Scientific Advisory Board
Geoff Tucker - - Member of Simcyp Scientific Advisory Board
Lawrence J. Lesko - 2015 Member of Simcyp Scientific Advisory Board
Eran Broshy 64 2022 Independent Director
Cynthia L. Collins 65 2021 Independent Director
Frederic Yves Bois - 2019 Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CERT Comments

Write your thoughts about Certara Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email